secwatch.observer — SEC 8-K summary
======================================

Issuer:     scPharmaceuticals Inc. (—)
CIK:        0001604950
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001193125-25-232754
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind completes acquisition of scPharmaceuticals for $5.35/sh plus CVR; stock delisted
--------------------------------------------------------------------------------

- Merger closed Oct 7, 2025; shareholders receive $5.35 cash + up to $1.00 CVR per share.
- Approximately 84.4% of shares tendered (73.5% valid tender + 10.9% guaranteed delivery).
- Company terminated existing credit agreement and repurchased revenue participation rights upon merger close.
- All directors resigned; new board appointed from MannKind (Michael Castagna, David Thomson, Chris Prentiss).
- Shares halted on Nasdaq; company will file Form 15 to deregister reporting obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604950/000119312525232754/0001193125-25-232754-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604950/000119312525232754/d20686d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-232754

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer